Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats.
paper
Cited
Public
Unavailable
- Authors
- PaΕucha, A; TatarczyΕska, E; BraΕski, P; Szewczyk, B; WieroΕska, J M; KΕak, K; Chojnacka-WΓ³jcik, E; Nowak, G; Pilc, A
- Year
- 2004
- Journal
- Neuropharmacology
- PMID
- 14680755
- DOI
- 10.1016/j.neuropharm.2003.09.006
It was well established that compounds which decrease glutamatergic transmission via blockade of NMDA or group I mGlu receptors produce anxiolytic- and antidepressant-like action in animal tests and models. Since group III metabotropic glutamate receptor (mGluR) agonists are known to reduce glutamatergic neurotransmission by the inhibition of glutamate release, we decided to investigate potential anxiolytic- and/or antidepressant-like effects of group III mGluR agonists, after central administration in rats. It was found that group III mGluR agonists, (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid (ACPT-I) and 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid (HomoAMPA), given intrahippocampally, produced a dose-dependent anxiolytic-like effect in the conflict drinking test. The effects of ACPT-I and HomoAMPA were reversed by (RS)-alpha-cyclopropyl-4-phosphonophenyl glycine (CPPG), group III mGluR antagonist. Moreover, a dose-dependent antidepressant-like action of group III mGluR agonists, ACPT-I and (RS)-4-phosphonophenylglycine (RS-PPG), but not HomoAMPA, was found in behavioral despair test, after intracerebroventricular injections, and the effect of ACPT-I was reversed by CPPG. The results obtained indicate that group III mGluR agonists produce anxiolytic- as well as antidepressant-like effects in behavioral tests, after central administration in rats. The reduction of glutamate release by group III mGluR activation may be a possible mechanism underlying anxiolytic- and antidepressant-like properties of the tested compounds. In conclusion, the results of our studies indicate that group III mGlu receptor agonists may play a role in the therapy of both anxiety and depression.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Association of single nucleotide polymorphisms in a glutamate receptor gene (GRM8) with theta power of event-related oscillations and alcohol dependence. | 2009 | 18618593 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Glutamate transporter activator LDN-212320 prevents chronic pain-induced cognitive impairment and anxiety-like behaviors in a mouse model. | Alotaibi G et al. | β | 2025 | β |
| Plasma Proteomic Profiling of a Group of Anxious Dogs by LC-MS/MS: A Case-Control Study. | Gaither C et al. | β | 2025 | β |
| Interactions between metabotropic glutamate and CB1 receptors: implications for mood, cognition, and synaptic signaling based on data from mGluR and CB1R-targeting drugs. | Stachowicz K | β | 2024 | β |
| mGluR7: The new player protecting the central nervous system. | Li P et al. | β | 2024 | β |
| Thalamocortical mGlu8 Modulates Dorsal Thalamus Excitatory Transmission and Sensorimotor Activity. | Nabit BP et al. | β | 2024 | β |
| Anxiolytic-like effects of an mGluR 5 antagonist and a mGluR 2/3 agonist, and antidepressant-like effects of an mGluR 7 agonist in the chick social separation stress test, a dual-drug screening model of treatment-resistant depression. | White SW et al. | β | 2023 | β |
| Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease. | Luessen DJ et al. | β | 2022 | β |
| Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization. | Khoodoruth MAS et al. | β | 2022 | β |
| New 1,2,4-oxadiazole derivatives with positive mGlu<sub>4</sub> receptor modulation activity and antipsychotic-like properties. | Stankiewicz A et al. | β | 2022 | β |
| Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review. | Frank D et al. | β | 2022 | β |
| Potential Pleiotropic Genes and Shared Biological Pathways in Epilepsy and Depression Based on GWAS Summary Statistics. | Lin H et al. | β | 2022 | β |
| International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors. | Gregory KJ et al. | β | 2021 | β |
| Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders. | Dogra S et al. | β | 2021 | β |
| Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-stroke depression. | Gruenbaum BF et al. | β | 2020 | β |
| Combined treatment of scopolamine and group III mGluR antagonist, CPPG, exerts antidepressant activity without affecting anxiety-related behaviors. | Ebrahimi-Ghiri M et al. | β | 2020 | β |
| The Cold Case of Metabotropic Glutamate Receptor 6: Unjust Detention in the Retina? | Palazzo E et al. | β | 2020 | β |
| The dorsal hippocampal group III metabotropic glutamate receptors are involved in morphine effect on memory formation in male mice. | Alijanpour S et al. | β | 2018 | β |
| Selective agonism of mGlu8 receptors by (S)-3,4-dicarboxyphenylglycine does not affect sleep stages in the rat. | Cavas M et al. | β | 2017 | β |
| The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders. | Peterlik D et al. | β | 2016 | β |
| The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect. | Pytka K et al. | β | 2016 | β |
| A novel mGlu4 selective agonist LSP4-2022 increases behavioral despair in mouse models of antidepressant action. | Podkowa K et al. | β | 2015 | β |
| Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety. | Raber J et al. | β | 2015 | β |
| Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders. | Kalinichev M et al. | β | 2014 | β |
| Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential. | Mercier MS et al. | β | 2014 | β |
| Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivo. | Domin H et al. | β | 2014 | β |
| Metabotropic glutamatergic receptors and their ligands in drug addiction. | Pomierny-ChamioΕo L et al. | β | 2014 | β |
| Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease. | Williams CJ et al. | β | 2014 | β |
| Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGluβ receptor. | SΕawiΕska A et al. | β | 2013 | β |
| Glutamate-based antidepressants: preclinical psychopharmacology. | Pilc A et al. | β | 2013 | β |
| Glutamate system as target for development of novel antidepressants. | Catena-Dell'Osso M et al. | β | 2013 | β |
| Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease. | Amalric M et al. | β | 2013 | β |
| Hippocampal group III mGlu receptor mRNA levels are not altered in specific mouse models of stress, depression and antidepressant action. | O'Connor RM et al. | β | 2013 | β |
| Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment. | O' Connor RM et al. | β | 2013 | β |
| Novel glutamatergic drugs for the treatment of mood disorders. | Lapidus KA et al. | β | 2013 | β |
| Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders. | Gregory KJ et al. | β | 2013 | β |
| Positive allosteric modulation of mGlu7 receptors by AMN082 affects sleep and wakefulness in the rat. | Cavas M et al. | β | 2013 | β |
| Regulation of the brain-gut axis by group III metabotropic glutamate receptors. | Julio-Pieper M et al. | β | 2013 | β |
| Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models. | Harvey BH et al. | β | 2012 | β |
| New perspectives in glutamate and anxiety. | Riaza Bermudo-Soriano C et al. | β | 2012 | β |
| Novel glutamatergic agents for major depressive disorder and bipolar disorder. | Machado-Vieira R et al. | β | 2012 | β |
| Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disorders. | Obregon D et al. | β | 2012 | β |
| Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders. | CΓ©lanire S et al. | β | 2012 | β |
| Regulation of N-methyl-D-aspartic acid (NMDA) receptors by metabotropic glutamate receptor 7. | Gu Z et al. | β | 2012 | β |
| Roles of glutamate signaling in preclinical and/or mechanistic models of depression. | Tokita K et al. | β | 2012 | β |
| Therapeutic potential of metabotropic glutamate receptor modulators. | HovelsΓΈ N et al. | β | 2012 | β |
| Differential effects of mGluR7 and mGluR8 activation on pain-related synaptic activity in the amygdala. | Ren W et al. | β | 2011 | β |
| Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. | Machado-Vieira R et al. | β | 2011 | β |
| The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration. | Nikiforuk A et al. | β | 2011 | β |
| The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. | Drago A et al. | β | 2011 | β |
| The role of glutamate on the action of antidepressants. | Hashimoto K | β | 2011 | β |
| An update on the role of glutamate in the pathophysiology of depression. | Mitchell ND et al. | β | 2010 | β |
| Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. | Cherlyn SY et al. | β | 2010 | β |
| Genome-wide association scan of trait depression. | Terracciano A et al. | β | 2010 | β |
| Glutamatergic modulators: the future of treating mood disorders? | Zarate C et al. | β | 2010 | β |
| Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. | WieroΕska JM et al. | β | 2010 | β |
| Metabotropic glutamate receptors: their therapeutic potential in anxiety. | Spooren W et al. | β | 2010 | β |
| Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. | Krystal JH et al. | β | 2010 | β |
| The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. | McEwen BS et al. | β | 2010 | β |
| Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. | Duty S | β | 2010 | β |
| Association of single nucleotide polymorphisms in a glutamate receptor gene (GRM8) with theta power of event-related oscillations and alcohol dependence. | Chen AC et al. | β | 2009 | β |
| Current investigational drugs for major depression. | Kulkarni SK et al. | β | 2009 | β |
| Design, synthesis and biological evaluation of novel bicyclo[1.1.1]pentane-based omega-acidic amino acids as glutamate receptors ligands. | Filosa R et al. | β | 2009 | β |
| Differential effects of MPEP and diazepam in tests of conditioned emotional response and Pavlovian-to-instrumental transfer suggests 'anxiolytic' effects are mediated by different mechanisms. | George SA et al. | β | 2009 | β |
| Emerging role of glutamate in the pathophysiology of major depressive disorder. | Hashimoto K | β | 2009 | β |
| Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. | WieroΕska JM et al. | β | 2009 | β |
| N-Methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors involved in the induction of sedative effects under an acute stress in neonatal chicks. | Yamane H et al. | β | 2009 | β |
| Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. | Machado-Vieira R et al. | β | 2009 | β |
| The effects of group III mGluR ligands on pentylenetetrazol-induced kindling of seizures and hippocampal amino acids concentration. | Maciejak P et al. | β | 2009 | β |
| The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. | Stachowicz K et al. | β | 2009 | β |
| The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. | Machado-Vieira R et al. | β | 2009 | β |
| Antidepressant-like activity of 8-Br-cAMP, a PKA activator, in the forced swim test. | BraΕski P et al. | β | 2008 | β |
| Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. | Bespalov AY et al. | β | 2008 | β |
| Bipolar disorder: candidate drug targets. | Zarate CA et al. | β | 2008 | β |
| Glutamate and neurotrophic factors in neuronal plasticity and disease. | Mattson MP | β | 2008 | β |
| Group III mGluR7 and mGluR8 in the amygdala differentially modulate nocifensive and affective pain behaviors. | Palazzo E et al. | β | 2008 | β |
| Mood disorders: regulation by metabotropic glutamate receptors. | Pilc A et al. | β | 2008 | β |
| Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. | PaΕucha-Poniewiera A et al. | β | 2008 | β |
| Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission. | Stachowicz K et al. | β | 2008 | β |
| Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis. | Matrisciano F et al. | β | 2008 | β |
| Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. | Palucha A et al. | β | 2007 | β |
| Antagonism of group III metabotropic glutamate receptors results in impairment of LTD but not LTP in the hippocampal CA1 region, and prevents long-term spatial memory. | Altinbilek B et al. | β | 2007 | β |
| Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. | Stachowicz K et al. | β | 2007 | β |
| Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. | WieroΕska JM et al. | β | 2007 | β |
| Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. | KΕak K et al. | β | 2007 | β |
| Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. | Palucha A et al. | β | 2007 | β |
| Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. | Lopez S et al. | β | 2007 | β |
| The effect of intrahippocampal injection of group II and III metobotropic glutamate receptor agonists on anxiety; the role of neuropeptide Y. | SmiaΕowska M et al. | β | 2007 | β |
| The role of hippocampus in anxiety: intracerebral infusion studies. | Engin E et al. | β | 2007 | β |
| Are compounds acting at metabotropic glutamate receptors the answer to treating depression? | Palucha A | β | 2006 | β |
| A temporally distinct role for group I and group II metabotropic glutamate receptors in object recognition memory. | Barker GR et al. | β | 2006 | β |
| Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. | Zarate CA et al. | β | 2006 | β |
| Correlation between plasma levels of glutamate, alanine and serine with severity of depression. | Mitani H et al. | β | 2006 | β |
| Design and synthesis of APTCs (aminopyrrolidinetricarboxylic acids): identification of a new group III metabotropic glutamate receptor selective agonist. | Schann S et al. | β | 2006 | β |
| Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. | Millan MJ | β | 2006 | β |
| Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. | Carlson PJ et al. | β | 2006 | β |
| Neuropharmacological analysis of caffeic acid in rats. | Pereira P et al. | β | 2006 | β |
| Synthesis and preliminary biological evaluation of (2S,1'R,2'S)- and (2S,1'S,2'R)-2-(2'-phosphonocyclopropyl)glycines, two novel conformationally constrained l-AP4 analogues. | Amori L et al. | β | 2006 | β |
| Ecdysone-based system for controlled inducible expression of metabotropic glutamate receptor subtypes 2, 5, and 8. | Downey PM et al. | β | 2005 | β |
| Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. | Karolewicz B et al. | β | 2005 | β |
| Excitatory amino acid neurotransmission. | Parsons CG et al. | β | 2005 | β |
| Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis. | Grueter BA et al. | β | 2005 | β |
| Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8. | Duvoisin RM et al. | β | 2005 | β |
| Innovative approaches for the development of antidepressant drugs: current and future strategies. | Schechter LE et al. | β | 2005 | β |
| Neurobehavioral and genotoxic aspects of rosmarinic acid. | Pereira P et al. | β | 2005 | β |
| Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. | PaΕucha A et al. | β | 2005 | β |
| Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. | Stachowicz K et al. | β | 2004 | β |
| Glutamate as a therapeutic target in psychiatric disorders. | Javitt DC | β | 2004 | β |